Evidence map›Paper›PMID 29671861›Full record

ArticleCardiology journal2019

P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.

Aleksandra Gasecka, Rienk Nieuwland, Edwin van der Pol, Najat Hajji, Agata Ćwiek, Kinga Pluta, Michał Konwerski, Krzysztof J Filipiak

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02931045 (Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction), which is not on this map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02931045 phase4completednot on this map

Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction

TypeinterventionalSponsorMedical University of WarsawRan2017 to 2019Enrolled60ConditionsMyocardial InfarctionArmsTicagrelor, Clopidogrel
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Extracellular vesicles: innovative cell-free solutions for wound repair.Frontiers in bioengineering and biotechnology · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Extracellular vesicles as personalized medicine.Molecular aspects of medicine · 2023
    Review
  12. Platelet-Derived Extracellular Vesicles in Arterial Thrombosis.Advances in experimental medicine and biology · 2023
    Article
  13. Review
  14. Review
  15. Observational
  16. Review
  17. Article
  18. Review
  19. Extracellular Vesicles in Skin Wound Healing.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Aleksandra GaseckaFirst Chair and Department of Cardiology, Medical University of Warsaw, Poland. a.agasecka@wum.edu.pl.
Rienk NieuwlandVesicle Observation Centre, and Laboratory of Experimental Clinical Chemistry, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands.
Edwin van der PolBiomedical Engineering & Physics, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands.
Najat HajjiVesicle Observation Centre, and Laboratory of Experimental Clinical Chemistry, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands.
Agata ĆwiekFirst Chair and Department of Cardiology, Medical University of Warsaw, Poland.
Kinga PlutaFirst Chair and Department of Cardiology, Medical University of Warsaw, Poland.
Michał KonwerskiFirst Chair and Department of Cardiology, Medical University of Warsaw, Poland.
Krzysztof J FilipiakFirst Chair and Department of Cardiology, Medical University of Warsaw, Poland.
Medical University of Warsaw · PLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActivated platelets release platelet extracellular vesicles (PEVs). Adenosine diphosphate (ADP) receptors P2Y1 and P2Y12 both play a role in platelet activation, The present hypothesis herein is that the inhibition of these receptors may affect the release of PEVs.

methodsPlatelet-rich plasma from 10 healthy subjects was incubated with saline, P2Y1 antagonist MRS2179 (100 μM), P2Y12 antagonist ticagrelor (1 μM), and a combination of both antagonists. Platelets were activated by ADP (10 μM) under stirring conditions at 37°C. Platelet reactivity was assessed by impedance aggregometry. Concentrations of PEVs- (positive for CD61 but negative for P-selectin and phosphatidylserine) and PEVs+ (positive for all) were determined by a state-of-the-art flow cytometer. Procoagulant activity of PEVs was measured by a fibrin generation test.

resultsADP-induced aggregation (57 ± 13 area under curve {AUC] units) was inhibited 73% by the P2Y1 antagonist, 86% by the P2Y12 antagonist, and 95% when combined (p < 0.001 for all). The release of PEVs- (2.9 E ± 0.8 × 10⁸/mL) was inhibited 48% in the presence of both antagonists (p = 0.015), whereas antagonists alone were ineffective. The release of PEVs+ (2.4 ± 1.6 × 10⁷/mL) was unaffected by the P2Y1 antagonist, but was 62% inhibited by the P2Y12 antagonist (p = 0.035), and 72% by both antagonists (p = 0.022). PEVs promoted coagulation in presence of tissue factor.

conclusionsInhibition of P2Y1 and P2Y12 receptors reduces platelet aggregation and affects the release of distinct subpopulations of PEVs. Ticagrelor decreases the release of procoagulant PEVs from activated platelets, which may contribute to the observed clinical benefits in patients treated with ticagrelor.

Indexed as

Adenosine DiphosphateBlood CoagulationBlood PlateletsExtracellular VesiclesHealthy VolunteersHumansPlatelet AggregationPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y1Receptors, Purinergic P2Y12Signal TransductionTicagrelorAdenosine DiphosphateN(6)-methyl-2'-deoxyadenosine 3',5'-diphosphateP2RY12 protein, humanP2RY1 protein, humanPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y1Receptors, Purinergic P2Y12TicagrelorADP receptorsextracellular vesiclesP2Y12 antagonistsplateletsticagrelor

Identifiers

PMID29671861
PMCPMC8083044
OpenAlexW2802207126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.